Form 4: Acrivon Therapeutics Chief Legal Officer Reports Routine Share Withholding for Tax

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, reported the withholding of 558 shares of common stock to satisfy tax obligations upon the vesting of restricted stock units, effective July 17, 2025.

Summary

• Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction involving the company's common stock.
• The transaction occurred on July 17, 2025, and involved the disposition of 558 shares.
• These shares were withheld by Acrivon Therapeutics to cover mandatory tax withholding requirements associated with the vesting of restricted stock units.
• The shares were disposed of at a price of $1.32 per share for tax purposes.
• Following this transaction, Mary Miller beneficially owns 35,765 shares of Acrivon Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes related to executive compensation, and does not reflect a discretionary sale or purchase by the insider.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a 'sell-to-cover' for tax purposes, which is common practice in the biotechnology and pharmaceutical industry when restricted stock units vest for executives.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and involves a small number of shares relative to the company's total outstanding shares.
• Employees: No direct impact beyond the reporting person.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Share Withholding, Restricted Stock Units, Tax Obligation, Corporate Officer